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ARTICLE
Rare De Novo Missense Variants in RNA Helicase DDX6
Cause Intellectual Disability and Dysmorphic Features
and Lead to P-Body Defects and RNA Dysregulation
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The human RNA helicase DDX6 is an essential component of membrane-less organelles called processing bodies (PBs). PBs are involved
in mRNAmetabolic processes including translational repression via coordinated storage of mRNAs. Previous studies in human cell lines
have implicated altered DDX6 inmolecular and cellular dysfunction, but clinical consequences and pathogenesis in humans have yet to
be described. Here, we report the identification of five rare de novo missense variants in DDX6 in probands presenting with intellectual
disability, developmental delay, and similar dysmorphic features including telecanthus, epicanthus, arched eyebrows, and low-set ears.
All five missense variants (p.His372Arg, p.Arg373Gln, p.Cys390Arg, p.Thr391Ile, and p.Thr391Pro) are located in two conserved motifs
of the RecA-2 domain of DDX6 involved in RNA binding, helicase activity, and protein-partner binding. We use functional studies to
demonstrate that the first variants identified (p.Arg373Gln and p.Cys390Arg) cause significant defects in PB assembly in primary fibro-
blast andmodel human cell lines. These variants’ interactions with several protein partners were also disrupted in immunoprecipitation
assays. Further investigation via complementation assays included the additional variants p.Thr391Ile and p.Thr391Pro, both of which,
similarly to p.Arg373Gln and p.Cys390Arg, demonstrated significant defects in P-body assembly. Complementing these molecular find-
ings, modeling of the variants on solved protein structures showed distinct spatial clustering near known protein binding regions.
Collectively, our clinical and molecular data describe a neurodevelopmental syndrome associated with pathogenic missense variants
in DDX6. Additionally, we suggest DDX6 join the DExD/H-box genes DDX3X and DHX30 in an emerging class of neurodevelopmental
disorders involving RNA helicases.
Introduction
Intellectual disability (ID) is a result of abnormal neurode-
velopment and affects at least 1% of the population. ID
typically presents in the first few years of life and is charac-
terized by impairments in cognition and adaptive
behavior. It is often accompanied by further delays in lan-
guage andmotor skills (developmental delay [DD]), as seen
in many neurodevelopmental disorders (NDDs). Given the
complexity of central nervous system development, the
genetic contribution to ID is quite heterogeneous. Patho-
genic variants in several hundred genes are now involved
in monogenic forms of ID, and each is responsible for a
subset of individuals.1
The widespread use of high-throughput sequencing has
allowed for a considerable increase in the identification
of these pathogenic variants. Large-scale studies that uti-
lize whole-exome sequencing (WES) or whole-genome
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sequencing (WGS) to look for pathogenic de novo variants
involved in autosomal-dominant forms of ID and NDD
continue to be performed, but these have focused more
on loss-of-function (LoF) variants. Hence, we can expect
that most genes sensitive to LoF events will be identified
in the next few years. On the contrary, identification of
missense variants that lead to ID or NDDs will continue
for some time because of the difficulty of defining pathoge-
nicity from large-scale sequencing data. In silico analyses
such as spatial clustering studies will help to identify novel
genes with clustered de novo pathogenic missense vari-
ants,2 but there remains a necessity for variant-specific
functional studies to confidently demonstrate cellular
dysfunction.
The hundreds of genes with pathogenic variants impli-
cated in ID encode proteins involved in different neuron-
specific or ubiquitous cellular processes: synaptic function
and architecture, cytoskeleton remodeling, regulation of
transcription through chromatin remodeling, or mRNA
posttranscriptional regulation such as maturation, export,
degradation, translation, etc.1,3,4 In eukaryotic cells, this
post-transcriptional regulation of gene expression is essen-
tial to proper neurodevelopment. A large variety of RNA-
binding proteins (RBPs) control mRNA localization, trans-
lation, storage, and decay in the cytoplasm, thus enabling
the spatio-temporal adjustment of protein synthesis
depending on cellular needs. One of the most illustrative
examples of how alterations of mRNA metabolism can
lead to NDD is Fragile-X syndrome, caused by pathogenic
variants in the gene FMR1,5 a gene encoding the FMRP pro-
tein, which is involved in the regulation of mRNA trans-
port and translation.6
In this study, we have assembled a cohort of children
with ID and other similar features who harbor rare
de novo variants in a single exon of DEAD-box helicase 6
(DDX6, MIM: 600326), a gene involved in RNA meta-
bolism. The DDX6 gene encodes an RNA helicase within
the Helicase Superfamily 2 (SF2).7 SF2 helicases function
on RNA in an ATP-dependent fashion. The helicases are
characterized by the presence of two RecA-like globular do-
mains, ancient protein construction modules found in
many motor-type proteins, that transit on or remodel
RNA and DNA. The domains are connected by a flexible
linker, and together they form a cleft for ATP and RNA
binding. Within SF2, the DExD/H-box helicases (DEAD,
DEAH, DExH. and DExD) are a subfamily sharing at
least eight conserved motifs and slight variations of
the signature helicase motif II for which they are named.
There are 50 DDX/DHX helicases in humans.8 Whereas
most of them are functionally uncharacterized, the data
available so far indicate that they have highly specific
functions.
DDX6 in particular is a DEAD-box protein characterized
in part by its Asp-Glu-Ala-Asp (DEAD)7 motif, and it is
involved in the regulation of mRNA decay and transla-
tion.9 It is also essential for forming cytosolic membrane-
less ribonucleoprotein (RNP) granules called processing
bodies (P-bodies or PBs),10,11 which are involved in RNA
metabolism through the coordinated storage of mRNAs
that encode regulatory functions.12,13 P-bodies are
observed in all eukaryotes. Like other RNP granules, such
as stress granules, germ granules, and neuronal granules,
their formation relies on RNA-protein networks, multiva-
lent low-affinity interactions, and liquid-liquid phase sep-
aration. Nevertheless, each RNP granule is distinct in its
composition and function. Currently, no neurological dis-
eases have been associated with P-body defects. We present
here the clinical phenotypes of individuals harboring rare
DDX6 missense variants and functional studies that indi-
cate these variants affect DDX6 function in terms of
mRNA decay and PB assembly, leading to a neurodevelop-
mental DDX6 syndrome.
Subjects and Methods
Subjects
Whole blood, saliva, buccal cells, skin fibroblasts, and/or photos
were obtained from research participants subsequent to informed
consent. The research on individuals within this study was per-
formed according to research protocols approved by the institu-
tional review boards or local ethics committees of the Transla-
tional Genomics Research Institute (TGen) and TGen’s Center
for Rare Childhood Disorders (C4RCD) (subjects 1 and 4), Stras-
bourg University Hospital (subject 2), and the Groningen Univer-
sity andRadboudUniversityNijmegenMedical Centers (subject 5).
All research participants and research groups, excluding subject 5,
were connected through GeneMatcher.14
DNA Sequencing and Bioinformatic Processing
This study involves subjects and data from five unrelated families
at different institutions in the US and Europe. Subject 1 and par-
ents underwent WES at TGen. Genomic DNA was extracted
from peripheral blood then isolated in a CLIA lab with the DNeasy
extraction kit (QIAGEN). Libraries were prepared with the Hyper
DNA Prep Kit for Illumina Platforms (Kapa Biosystems). Exome
capture was performed with the SureSelectXT Target Enrichment
Platform with Clinical Research Exome baits (Agilent Technolo-
gies). Sequencing was performed by 100 base pair (bp) paired-
end sequencing on a HiSeq4000 instrument (Illumina). Reads
were aligned to the human genome (Hg19/GRCh37) with the Bur-
rows-Wheeler Aligner (BWA mem v.0.7.8).15 PCR duplicates were
identified with Picard MarkDuplicates v1.79. Base quality recali-
bration and indel realignment were performed with the Genome
Analysis Toolkit (GATK v3.5-1).16 Variants were jointly called
with HaplotypeCaller and recalibrated with GATK17. Quality con-
trols were conducted with FASTQC v0.11.5. Called variants were
annotated with SnpEff v3.0a18 against Ensembl GRCh37.66 and
filtered against dbSNP137 1000 Genomes Project (minor allele fre-
quency < 0.05), SnpEff Impact: high þ moderate, GATK quality
score > 300, and known genes. We used prediction scores from
dbNSFP (Database for Nonsynonymous SNP’s Functional Predic-
tions) and an internal annotation tool for filtering. Subject 2
underwent a simplex WES (Dijon Hospital) as previously
described.19 When no pathogenic variant was found, trio WGS
was performed at the Centre National de Recherche en Ge´nomi-
que Humaine (CNRGH). Libraries were prepared and sequenced
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with the Illumina TruSeq DNA PCR-Free Library Preparation Kit
and sequenced (3 lanes/genome, paired-end 100 bp) on a
HiSeq2000 platform from Illumina (Illumina) to obtain a depth
of 303 for each sample. Reads were aligned on the human genome
(GRCh37) with bwa software,15 duplicate sequences were filtered
out with Sambamba tools, and an additional step of realignment
was performed with GATK programs (IndelRealigner). Variants
were identified via 4 programs (UnifiedGenotyper and Haploty-
peCaller from GATK, Platypus,20 and Samtools). Single nucleotide
variations (SNVs) falling in a coding region or in a genomic region
of a known ID gene were annotated with Varank;21 annotations
included information about the inheritance (de novo versus in-
herited variants). Comparison of SNVs identified genome-wide
in the proband and his parents resulted in a list of potential
de novo variants. Structural variants were detected with SoftSV22
and copy number variants with CANOES,23 and then variants
were annotated by AnnotSV.24 For subject 4, genomic DNA from
the proband and respective parents was sequenced at GeneDx.
The exonic regions and flanking splice junctions of the genome
were captured with the IDT xGen Exome Research Panel v1.0.
Massively parallel (NextGen) sequencing was done on an Illumina
systemwith 100 bp or greater paired-end reads. Reads were aligned
to human genome build GRCh37/hg19 and analyzed for sequence
variants with a custom-developed analysis tool. Additional
sequencing technology and variant interpretation protocol has
been previously described.25 The general assertion criteria for
variant classification are publicly available on the GeneDx ClinVar
submission page (seeWeb Resources). Subject 5 and parents under-
went trio WES. We used Sanger sequencing to confirm DDX6
variants in all affected probands.
Variant Prioritization and Analysis
Candidate variants were categorized into inheritance patterns,
including de novo, recessive, compound heterozygous, and
X-linked, and prioritized by variousmethods including variant fre-
quency (less than 2% or absent) via the Genome Aggregation
Database (gnomAD).26We performed further filtering of candidate
genes and variants from the prediction of damaging effects by
using in silico tools such as the gnomAD v2.1.1 probability of
loss-of-function intolerance score (O/E, pLI) and missense Z score,
Combined Annotation Dependent Depletion (CADD),27 Genomic
Evolutionary Rate Profiling (GERP),28 SIFT,29 PolyPhen 2,30
SNAP2,31 Envision,32 biological relevance, and association with
human disorders with a neurodevelopmental phenotype in the
literature. Candidate variants were interpreted according to the
guidelines published by the American College of Medical Genetics
and Genomics (ACMG).33
RNA Sequencing and Gene Expression Analysis of
Fibroblasts
Experiments were performed in duplicate from two different fibro-
blast pellets obtained from subject 2 (S2). Total RNA was extracted
with the RNeasymini kit (QIAGEN), including a DNase treatment.
RNA levels and quality were quantified with a Nanodrop spectro-
photometer and a 2100 Bioanalyzer (Agilent). mRNA libraries of
template molecules suitable for high-throughput DNA sequencing
were created with the TruSeq RNA Sample Preparation v2 Kit from
200 ng of total RNA. S2 was prepped with eight other individuals
affected by Bardet Biedl syndrome or other causes of ID not related
to DDX6 mutation, and the subsequent libraries were sequenced
on one run with the Illumina Hiseq 4000 sequencer as paired-
end 100 base reads. Image analysis and base calling were per-
formed with RTA 1.18.61 and CASAVA 1.8.2. Reads (403,718,870
and 299,879,030) weremapped onto the hg19 assembly of the hu-
man genome with TopHat 2.0.14 and the Bowtie 2-2.1.0 aligner.
The raw sequencing data generated in the course of this RNA study
are not publicly available, but more details are available on de-
mand. Gene expression was quantified with HTSeq-0.6.134 and
gene annotations from Ensembl release 75. Only uniquely-map-
ped and non-ambiguously assigned reads were retained for further
analyses. Read counts were then normalized across libraries with
the median-of-ratios method proposed by Anders and Huber.35
To check whether the normalizationwas correctly performed, rela-
tive log expression (RLE) plots were drawn to check that the distri-
butions are centered around the zero line and as tight as possible.
Comparisons to the eight aforementioned individuals with other
neurodevelopmental or sensorineural conditions unrelated to
DDX6 mutation were performed according to the statistical
method proposed by Anders and Huber.35 We used the Wald test
to estimate the p values, and we adjusted them for multiple
testing with the Benjamini and Hochberg method.36 Significant
differentially-expressed (DE) genes were analyzed with the Data-
base for Annotation, Visualization, and Integrated Discovery
(DAVID 6.7). We used biological processes and molecular func-
tions of the Gene Ontology Consortium (GO), as well as pathways
from KEGG (Kyoto Encyclopedia of Genes and Genomes), for the
functional annotations. The list of genes known or suspected to be
involved in ID was extracted from the SysID database (see Web
Resources). Genes with ten or more reads detected (on average)
were considered as expressed in fibroblasts.
Molecular Modeling of DDX6 and Missense Variant
Impact Prediction
High-resolution crystal structures for human DDX6 in an open
conformation (PDB: 4CT5) and closed conformation in complex
with the CNOT1 MIF4G and 4E-T CHD domains (PDB: 5ANR)
were obtained from Protein Data Bank (originally submitted by
Mathys et al.37 and Ozgur et al.9). Three-dimensional (3D) mapping
of gnomAD v2.1.1 missense variants and DDX6 variants
c.1115A>G (p.His372Arg), c.1118G>A (p.Arg373Gln), c.1168T>C
(p.Cys390Arg), c.1171A>C (p.Thr391Pro), and c.1172C>T
(p.Thr391Ile) was performed with PyMOL v2.1.1 and the UCSF
Chimera package.38
Cell Culture, siRNA, Plasmids, and Transfection
Fibroblasts from Subject 2 and one sex-matched control individ-
ual, as well as fibroblasts from subject 1 and her parents, were
maintained in 50% low-glucose DMEM and 50% nutrient mixture
F10-Ham, supplemented with 10% fetal calf serum and 1% peni-
cillin and streptomycin. Human embryonic kidney HEK293 and
human epithelioid carcinoma HeLa cells were maintained in
high-glucose DMEM supplemented with 10% fetal calf serum
and 1% penicillin and streptomycin.
To silence endogenous DDX6, HeLa cells were transfected via
Lullaby (OZ Biosciences) at the time of their plating with 0.7 mg
(35mmPetri dish) or 4.5 mg (100mmPetri dish) of siRNA targeting
the 30UTR of DDX6 mRNA (Eurofins Genomics). The sequence of
the siRNA targeting the 30UTR of DDX6 mRNA was: 50-GGAA
CUAUGAAGACUUAAAdTdT-30.11 24 h later, cells were transfected
with 1 mg or 5 mg of plasmid DNA (35 mm or 100 mm Petri dish,
respectively) via Genjet plus DNA (SignaGen Laboratories).
The p.Arg373Gln, p.Cys390Arg, p.Thr391Ile, and p.Thr391Pro
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variants were introduced in the previously described FLAG-DDX6-
HA plasmid10 with the InFusion Advantage PCR cloning kit (Clon-
tech) and the following oligonucleotides (Eurofins Genomics):
Arg373Gln_F: 50-GGAACATCAAAATCGTGTATTTCATGATTTC
CGAAATGGCTTATG-30
Arg373Gln_R: 50-CGATTTTGATGTTCCTGCCTCATTTTAGCAT
GAATATAGAAGCAA-30
Cys390Arg_F: 50-ATCTTGTTCGCACTGATCTGTTTACCCGAGG
TATTGATATACAAG-30 Cys390Arg_R: 50-CAGTGCGAACAAGATT
GCGGCATAAGCCATTTCGGAAATCATGAA-30
Thr391Ile_F: 50-TGTTTGCATTGATCTGTTTACCCGAGGTATTG
ATATACAAGCTGT-30
Thr391Ile_R: 50-AGATCAATGCAAACAAGATTGCGGCATAAGC
CATTTCGGAAATCA-30
Thr391Pro_F: 50-TTGTTTGCCCTGATCTGTTTACCCGAGGTAT
TGATATACAAGCTG-30
Thr391Pro_R: 50-GATCAGGGCAAACAAGATTGCGGCATAAGC
CATTTCGGAAATCAT-30. Cells were harvested 60 h after plating.
Immunofluorescence
Cells were grown on glass coverslips in 35 mm Petri dish and fixed
in methanol for 3 min at 20C. Cells were blocked 10 min in 2%
BSA (bovine serum albumin) in PBS (phosphate-buffered saline),
incubated 1 h with the primary antibody, rinsed with PBS, incu-
bated 1 h with a fluorochrome-conjugated secondary antibody,
and rinsed in PBS. Slides were mounted in Citifluor (Citifluor).
For complementation assays, microscopy was performed on a Le-
ica DMRmicroscope (Leica) with a 633 1.32 oil immersion objec-
tive lens. Photographs were taken with a Micromax CCD cam-
era13 (Princeton Instruments) driven by the Metamorph
software. For fibroblast imaging, epifluorescence microscopy was
performed on an inverted Zeiss Z1 microscope (Zeiss) equipped
with a motorized stage using a 63 3 1.4 oil immersion objective
lens and running under the Zen software. Photographs were ob-
tained with an Axiocam 506 mono camera (Zeiss). Images were
processed with ImageJ. To quantitate PBs, we used the plugin
Spot Detector of the open bioimage informatics platform Icy39
(seeWeb Resources). Primary antibodies were rabbit DDX6 (Novus
Biologicals), rabbit LSM14A (Merck-Millipore), mouse EDC4
(Santa Cruz Biotechnology), and rabbit HA and mouse FLAG M2
(Sigma-Aldrich). Secondary antibodies were purchased from
Jackson ImmunoResearch Laboratories.
Immunoprecipitation and Immunoblot Analyses
For immunoprecipitation, HEK293 cells transfected with FLAG-
DDX6-HA plasmids were grown in 100 mm Petri dish, washed
twice in PBS, scrapped in 2 mL PBS, and pelleted at 360 g. Pellets
were resuspended in 0.5 mL lysis buffer (50 mM Tris [pH 7.5],
125 mM NaCl, 0.5% NP40, 1mM EDTA, 1mM EGTA, 1mM DTT,
and 5% glycerol) supplemented with RNaseA (10 mg/mL) and 23
EDTA-free protease inhibitor cocktail (Roche Diagnostics). After
30 min of incubation at 4C, nuclei were pelleted at 500 g for
10 min at 4C, and proteins from the supernatant were immuno-
precipitated according to the following method: 1–3 mg of the
cytoplasmic extracts was incubated at 4C for 2 h with anti-
FLAG M2 magnetic beads (Sigma-Aldrich). After washing, bound
proteins were eluted with SDS loading buffer. Immunoprecipitated
proteins were migrated along with 30 mg of control cytoplasmic
lysate and analyzed by immunoblot as described below. Signals
were quantified from scanned X-ray films with ImageJ, normalized
to the signal obtained with FLAG M2 antibody in the same
experiment, and expressed as a relative percentage of binding pro-
teins via the wild-type FLAG-tagged DDX6.
For immunoblot analyses, cytoplasmic extracts were prepared as
described,40 except that soluble and insoluble proteins were sepa-
rated by centrifugation at 500 g for 10 min at 4C. After immuno-
precipitation, proteins were separated on a NuPage 4%–12% gel
(Invitrogen, Thermo Fischer Scientific) and transferred to a PVDF
(poly-vinylidene fluoride) membrane (Perkin Elmer). After block-
ing in PBS containing 5% (wt/vol) nonfat dry milk for 1 h at
room temperature, themembranewas incubated with the primary
antibody overnight at 4C, rinsed in PBS, and incubated with
horseradish peroxidase-conjugated secondary antibody for 1 h at
room temperature. After washing in PBS, proteins were detected
with Western lightning plus ECL kit (Perkin Elmer) and visualized
by exposure to CL-XPosure film (Pierce, Thermo Fischer Scientific).
Primary antibodies included rabbit DDX6 (Novus Biologicals), rab-
bit ribosomal S6 (Cell Signaling Technology), mouse FLAG M2
(Sigma-Aldrich), rabbit 4E-T (Abcam), rabbit LSM14A (Merck-
Millipore), rabbit LSM14B (Sigma-Aldrich), rabbit PAT1B (Cell
Signaling Technology), rabbit EDC3 (Abcam), and mouse EDC4
(Santa Cruz Biotechnology). The secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories.
Results
Identification of RareDe NovoMissense Variants inDDX6
in Individuals with ID
Individual analyses of the five families did not reveal any
known pathogenic variants in genes with associated syn-
drome(s) closely overlapping the clinical features of the
probands. The WES study for Subject 1 (S1) did reveal a
de novo missense variant in a gene, DDX6 (GenBank:
NM_004397.5; p.Arg373Gln, not previously associated
with human disease (Table 1). Data also showed com-
pound-heterozygous missense variants of unknown signif-
icance (VUSs) in DNAH11 (MIM: 603339) (Table S1).
DNAH11 is associated with autosomal-recessive ciliary
dyskinesia, primary, 7, with or without situs inversus
(CILD7) (MIM: 611884), predominately through LoF mu-
tations. The clinical features of CILD7 do not include ID
or resemble S1’s phenotype. Furthermore, DNAH11 pos-
sesses significantly more missense variation than expected
in gnomAD (Z score ¼ 5.61), and ClinVar contains no
confirmed pathogenic missense variants. Thus, the VUS
was excluded as a candidate. Subject 2 (S2) first underwent
an ID gene panel sequencing, singleton WES, and finally
WGS of the nuclear family. Among the 146 putative
de novo variants identified in the proband, only one
occurred in a coding region; this variation was a missense
change of p.Cys390Arg in DDX6. No other candidate
variant(s) were identified in coding or genomic regions
of genes known to be involved in ID. Two additional
de novomissense variants in DDX6, p.Thr391Ile (in subject
3 [S3]) and p.Thr391Pro (in subject 4 [S4]), were identified
by trio WES in unrelated individuals with developmental
disorders (GeneDx). Subject 4 carries an additional hemi-
zygous missense VUS in the gene SLC16A2 (MIM:
30095), associated with Allan-Herndon-Dudley syndrome
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(AHDS, MIM: 300523), but this diagnosis does not fit with
his clinical history (Table S1). A key feature of males with
AHDS is abnormal triiodothyronine (T3) and thyroxine
(T4) levels. Repeat thyroid studies including dosages of
T3 and T4 (free, total, and reverse) in S4 were all normal.
During the final stages of this study, a fifth individual
(subject 5 [S5]) with a single de novo missense variant of
p.His372Arg in DDX6 was identified by WES. For all indi-
viduals, no other variants except the DDX6 missense
changes described above were classified pathogenic or
likely to be pathogenic according to ACMG guidelines.
Clinical Features of Individuals Carrying De Novo
Missense Variants in DDX6 Exon 11
We could retrieve clinical information for four of the in-
dividuals carrying de novo missense variants in DDX6.
These probands are from unrelated families in both the
USA and Europe. The affected individuals present with
NDD of unknown etiology and range between the ages
of 4 to 13 years at last clinical assessment. The parents
are noted to be without any significant health problems.
Phenotyping of the four affected probands showed over-
lap of clinical features and minor variation in severity
across individuals (Table 2). Clinical features include
ID (4/4); DD (4/4); mild to moderate cardiac anomalies
(3/4); hypotonia (3/4); gait instability (3/4); and hand,
foot, and genitourinary abnormalities (3/4). Other fea-
tures present include mild to moderate MRI anomalies,
a small head circumference (< 2 standard deviations
[SDs]), congenital hydronephrosis with vesicoureteral
reflux, mild obesity, and autistic traits. The probands
also share common facial dysmorphic features including
a high forehead, a bulbous nasal tip, widely spaced eyes,
arched eyebrows, and low-set ears (Figure 1). Expanded
summaries can be found in Supplemental Data: Individ-
ual Reports.
DDX6 Missense Variants Found in Affected Individuals
Are Absent from Population Databases, Evolutionarily
Conserved, and Spatially Clustered within Protein
All de novomissense variants identified in affected individ-
uals are located in exon 11 of DDX6. This exon is present
in all DDX6 isoforms and codes for the conserved motifs
QxxR and V within the second RecA-2 domain of the heli-
case core. The variants have not been observed in the
gnomAD database, which contains genetic data from
140 thousand individuals and is depleted of severe pedi-
atric disorders.DDX6 is highly intolerant to LoF variants as
indicated by gnomAD’s (v2.1.1) observed/expected LoF
ratio of 0.04 (confident interval [0.01–0.17]), and there
is only one heterozygous LoF change reported in the
penultimate exon of its canonical isoform (GenBank:
NM_004397.5). DDX6 was also found to have significant
intolerance to missense change, indicated by a gnomAD
Z score of 3.93 (observed/expected ratio of 0.34
[0.29–0.41]), suggesting selection pressure against amino
acid changes.26 In particular, exon 11 (aa 371–391) wasTa
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Table 2. Clinical Features of Individuals with De Novo Pathogenic Variants in DDX6
Subject 1 Subject 2 Subject 4 Subject 5
Sex/age at last exam female/5 years male/6 years male/10 years female/13 years
DDX6 variant
(GenBank: NM_004397.5)
c.1118G>A (p.Arg373Gln) c.1168T>C (p.Cys390Arg) c.1171A>C (p.Thr391Pro) c.1115A>G (p.His372Arg)
Inheritance de novo de novo de novo de novo
Intellectual disability þ þ þ þ
Developmental delay þ þ þ þ
Speech delay þ (nonverbal) þ þ þ
Small head circumference
(<2 SD)
þ þ  
MRI brain anomalies hypoplastic posterior corpus
callosum (27 months)
  wide liquor spaces, thin corpus callosum,
mild delay of myelination
Seizures   history of staring spells, normal EEG 
Hypotonia mild, axial þ  þ
Gait walked with support until
27 months, many falls from
balance issues
 instability, delayed coordination,
toe-walking
trouble with walking, using wheelchair for
longer distances
Extremities (hands, feet) overriding second toes bilaterally syndactyly II-III of the feet tapered fingers, hypermobile flat feet tapered fingers, overriding toes
Facial dysmorphia hypertelorism, small palpebral fissures,
bilateral epicanthus, arched eyebrows
hypertelorism, small palpebral fissures,
bilateral epicanthus
arched eyebrows high-bossing forehead, bitemporal
narrowness, telecanthus, epicanthus
Eyes strabismus, hypermetropia strabismus, hypermetropia slight anisocoria strabismus, hypermetropia
Ears low-set, petite, and rotated.
overfolded superior pinna
low-set  overfolded upper helix
Mouth high, arched palate; smooth
prominent philtrum
  
Heart abnormalities patent foramen ovale, aberrant right
subclavian artery, cardiac murmur
atrial septal defect with spontaneous
closing
no imaging patent foramen ovale
Congenital hydronephrosis/
vesicoureteral reflux
þ   
Feeding or Gastrointestinal
difficulties
þ (G-tube) þ history of abdominal pain, constipation,
unexplained elevated LFTs- resolved

Genitourinary anomalies anteriorly placed anus, normal genitalia cryptorchidism micropenis 
Other recurrent infections, oligohydramnios,
malrotated right pelvic kidney
supernumerary nipple, inguinal hernia hyposmia/anosmia, femoral retroversion,
external tibial torsion, progressive striae on
legs, photosensitivity with severe eczematous
rash on hands, advanced bone age, mild
truncal obesity, anxiety, motor stereotypies
single umbilical artery, delayed closure of
fontanel, mild hip dysplasia, pes plano
valgus, mild obesity, scoliosis
5
1
4
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
1
0
5
,
5
0
9
–
5
2
5
,
S
e
p
te
m
b
e
r
5
,
2
0
1
9
found highly depleted of nonsynonymous variations in
gnomAD (Figure 2A). The specific variants identified in
the probands lead to changes at conserved positions and
are predicted to be deleterious by in silico analysis tools
(Table 1 and Figure 2B). The QxxR motif containing
Arg373 is conserved in 33/35 DEAD-box family members,
and the varying residues are structurally and chemically
similar (Glutamine). In Motiv V, residue 390 maintains
small, uncharged residues throughout the DEAD-box pro-
tein family (35/35), and Thr391 is conserved in every
member (Figures S1 and S2). Furthermore, mapping of
the variants on a 3D structure of DDX6 in complex with
the CNOT1 MIF4G and 4E-T CHD domains37 showed
that proband variants spatially cluster near to or at the pro-
tein surface in a region depleted of missense variants in
gnomAD populations (Figures 2C and 2D) and close to
the 4E-T interaction surface, suggesting that this region is
of functional importance for DDX6.
Mutant DDX6 Proteins Are Defective in PB Assembly
Because DDX6 is known to be involved in the formation
of cytoplasmic PBs, we first analyzed the presence of
PBs in fibroblasts obtained from S2, who carried the
p.Cys390Arg change, and from an unrelated age-matched
control subject. The cells were analyzed by immunofluo-
rescence that used antibodies against DDX6 and a second
PB marker, EDC4 (Figure 3A). Although most fibroblasts
from the control subject showed numerous PBs detected
by both DDX6 and EDC4 antibodies, only some of the
fibroblasts obtained from S2 contained PBs. However,
immunoblot analyses indicated that a similar amount of
DDX6 protein was present in these cells (Figure S3A), sug-
gesting a functional defect in this variant. Fibroblasts
were also obtained from S1, who carried the p.Arg373Gln
variant, and from her parents. Again, immunoblot anal-
ysis showed similar levels of DDX6 protein in the three
cell samples (Figure S3A), whereas immunostaining indi-
cated that the proband’s cells contained fewer PBs than
the mother’s (Figures S3B and S3C). The father’s cells
grew slowly, however, and possibly related to that, had
an intermediate number of PBs: lower than the mother’s,
but higher than S1’s cells (Figures S3B and S3C). To
confirm the specific defect of PBs in S1, we therefore sub-
mitted the three cell cultures to a mild cold shock at 30C
for 2 h because we showed previously that such a treat-
ment results in increased number and size of PBs in estab-
lished cell lines.10 With this treatment, 90% of the par-
ents’ cells contained numerous PBs, whereas 70% of S1’s
cells remained devoid of PBs (Figures 3B and 3C). More-
over, in the 30% of cells with PBs, the numbers remained
low, thus confirming a specific PB defect in the proband
cells.
We then investigated the ability of the different
variant-containing DDX6 proteins to assemble PBs in
a model human cell line.11 Plasmids encoding the
four DDX6 initially-identified variants (p.Arg373Gln,
p.Cys390Arg, p.Thr391Ile, and p.Thr391Pro) fused to
FLAG and HA tags were transfected in HeLa cells
(Figure S4A). The variant proteins localized in PBs, as
was assessed by immunofluorescence that used LSM14A
as a P-body marker (Figure S4B). However, they dramati-
cally affect PB assembly, as was tested by the following
complementation assay (Figure 4A). In brief, we depleted
cells of endogenous DDX6 by using siRNA targeting the
30UTR of DDX6 mRNA (Figure 4B), which resulted, as ex-
pected,11 in PB disassembly (Figures 4A and 4C). 24 h
later, cells were transfected with wild-type or mutant
FLAG-DDX6-HA plasmids and analyzed 40 h later for
Figure 1. Individuals with Intellectual Disability and Developmental Delay and Rare De Novo Missense Variants in DDX6
Pictures of individuals with rare de novo missense variants in DDX6 (Subjects S1, S2, S4, and S5).
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Figure 2. Localization of the Different De Novo Missense Variants in DDX6
(A) Linear representation of the DDX6 protein (GenBank: NP_004388) with highlighted functional DExD/H-box motifs. De novo
missense variants identified in individuals with ID are indicated by red dashed lines, and missense variants observed in the gnomAD
population are plotted in orange with an indication of the number of individuals carrying them. Motif residue numbers and colors
are as follows: motifs Q (115–123) and GG (201–203) in yellow, motifs I (140–146) and II (DEAD) (246–249) in dark green, motifs
Ia (171–181) and Ib (222–225) in orange, motif IV (338–340) and V (395–399) in light green, and motifs III (277–279), QxxR
(370–373), and VI (419–427) in gray. Motifs Q, I, II, V, and VI are involved in ATP binding, and motifs GG, QxxR, Ia, Ib, IV, and V
are involved in RNA binding. Motif III is involved in intramolecular interactions.13
(B) A heatmap spanning the linear DDX6 protein representing in silico impact (effect) predictions of all possible amino acid substitution
mutations in DDX6 from the SNAP2 classifier. Dark red indicates a strong signal for effect, white indicates a weak signal, and blue
indicates a strong signal for neutral or no effect.
(C) Mapping of missense variants identified in the gnomAD population (blue spheres) and in probands (red spheres) on a 3D represen-
tative structure of DDX6 in complex with the CNOT1 MIF4G (pink) domain and the 4E-T CHD (green) domain (PDB: 5ANR). The two
RecA-like units of DDX6 are colored in gray (helicase ATP-binding domain) and yellow (helicase C-terminal domain).
(D) A hydrophobicity surface model of DDX6 (PDB: 4CT5) created with Chimera. Kyte-Doolittle scale coloring was used; colors range
from dodger blue for the most hydrophilic, to white at neutral, to orange-red for the most hydrophobic regions. Missense variants
identified in probands have been highlighted in yellow.
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the presence of PBs (Figures 4A and 4C). Whereas the
wild-type DDX6 restored PB assembly, no or very few
PBs were observed when we used the mutant proteins;
there was less than 5% efficiency for the p.Arg373Gln,
p.Cys390Arg, and p.The391Ile variants as compared to
the wild-type protein, and 17% for the p.Thr391Pro
variant (Figures 4A and 4C). We obtained similar results
by using EDC4 as a PB marker (Figure S4C). This indi-
cated that the mutant DDX6 proteins were unable to
replace the endogenous DDX6 for PB formation.
Figure 3. Fibroblasts from Individuals S1
and S2 Contain a Low Number of PBs
(A) Fibroblasts from an unrelated, age-
matched control individual and from
S2, who carried the DDX6-p.Cys390Arg
variant, were immunostained with DDX6
and EDC4 antibodies. Nuclei were stained
with DAPI. Arrows point to some selected
PBs within cells. The scale bar represents
20 mm.
(B) Fibroblasts from S1, who carried the
DDX6-p.Arg373Gln variant, and her
healthy parents were analyzed as in (A)
except that cells were grown for 2 h at
30C before fixation. The scale bar repre-
sents 20 mm.
(C) Quantification of the fibroblasts with
PBs. PB-containing cells were counted and
plotted as a percentage of total cells (98 to
126 cells from three and four independent
experiments for S2 and S1, respectively).
Error bars, SD; t test: p < 0.0001 for both
probands, as compared with their respective
control.
Mutant DDX6 Proteins Are
Defective in Interactions with
Protein Partners Key to PB
Assembly
Previously, we showed that three fac-
tors, DDX6, LSM14A, and 4E-T, are
required and their interactions essen-
tial for PB assembly.10,11,41 Mutating
the DDX6 FDF-binding pocket
(Mut1: four substitutions introduced
between residues 320 and 3319,42,43)
prevents the binding of LSM14A and
4E-T and strongly reduces PB forma-
tion.10 Because the variants identified
inDDX6 are located close to the Mut1
mutations, we hypothesized that they
could also alter interactions between
DDX6 and these protein partners. To
address this question, plasmids en-
coding wild-type and mutant DDX6
(p.Arg373Gln and p.Cys390Arg) fused
to FLAG and HA were transfected in
HEK293 cells after depletion of the
endogenous DDX6 protein, then
immunoprecipitated 48 h later with
FLAG antibodies, and the protein complexes were
analyzed by immunoblot (Figure 4D). First, both mutant
DDX6 proteins showed reduced binding to 4E-T and
LSM14A, as compared to wild-type DDX6, and the defect
was stronger for the p.Arg373Gln mutant than for the
p.Cys390Arg mutant. This is consistent with the inability
of these mutants to assemble PBs in the complementation
assay. A binding defect was also observed for other DDX6
partners: LSM14B binding was as affected as LSM14A bind-
ing in the case of both mutants, whereas other bindings
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were defective only in the case of the p.Arg373Glnmutant.
This included a strong defect in PAT1B binding and some
impairment of EDC3 and EDC4 binding, as well. Overall,
the p.Arg373Gln mutant protein was the most defective
at interacting with its partners, especially those acting as
translation repressors (LSM14A, 4E-T, and PAT1B).
p.Cys390Arg Variant Cells Accumulate mRNAs Involved
in Translational Regulation, DDX6 mRNA Targets, and
PB-Excluded mRNAs
Transcriptomic (RNAseq) analysis was performed from skin
fibroblasts obtained from S2 (who carried the p.Cys390Arg
variant) and compared to eight unrelated individuals with
other neurodevelopmental or sensorineural conditions un-
related to DDX6 mutation. More than 1,000 genes were
found to be significantly (p-adjusted < 0.05) differentially
expressed (DE) (Figure 5A); these included 493 upregulated
and 979 downregulated protein-coding genes (Table S2).
Enrichment analysis via DAVID44 demonstrated that the
set of genes significantly upregulated was enriched for
Gene Ontology ‘‘biological process’’ and ‘‘molecular func-
tion’’ terms related to protein translation; these terms
included ‘‘SRP-dependent cotranslational membrane
targeting’’ (GO: 0006614, fold enrichment FE ¼ 12.5,
adjusted p value ¼ 2.0 3 1018) or ‘‘formation of transla-
tion preinitiation complex’’ (GO: 0001731, FE ¼ 11.3,
adjusted p value ¼ 3.3 3 102), or ‘‘structural component
of the ribosome’’ (GO: 003735, FE ¼ 5.4, adjusted
p value ¼ 1.5 3 109) (Figure 5B). This enrichment was
confirmed by analyzing KEGG pathways (‘‘ribosome,’’
map03010 FE ¼ 7.9, adjusted p value ¼ 7.2 3 1015).
More specifically, 4 out of the 14 expressed eIF3 translation
Figure 4. Rare Missense Variants in DDX6 Affect its Interaction with Protein Partners and PB Formation
(A–C) Mutated DDX6 proteins are defective for PB assembly.
(A) Complementation assays. HeLa cells were depleted for endogenousDDX6 by transfection of a siRNA targeting theDDX6 30UTR at the
time of plating (control). After 24 h, cells were transfected or not with indicated FLAG-DDX6-HA plasmids. 40 h later, cells were analyzed
by immunofluorescence using the indicated antibodies. The scale bar represents 10 mm.
(B) Protein extracts from cells transfected or not with siRNA were analyzed by immunoblot with the indicated antibodies to verify the
DDX6 depletion. The DDX6 signal, normalized using the ribosomal protein S6, is indicated below.
(C) The number of PBs per cell was counted in three independent experiments (21–67 cells per experiment) and expressed as the relative
percentage of PBs compared to the complementation with wild-type DDX6. FLAG-DDX6-p.Arg373Gln, -p.Cys390Arg, -p.Thr391Ile, and
-p.Thr391Pro correspond to the DDX6 variants identified in subjects 1, 2, 3, and 4, respectively. Error bars, SD; t test: p < 0.0001 for all
mutants, as compared to wild type.
(D) DDX6 pathogenic variants impair ligand binding. HEK293 cells were depleted for endogenous DDX6 and transfected 24 h later with
the indicated FLAG-DDX6-HA plasmids as in (A–C). 48 h later, proteins were extracted in the presence of RNaseA and immunoprecip-
itated with anti-FLAG M2 antibodies. 10% of the eluates were analyzed by immunoblot using the same antibody (bottom frame),
whereas bound proteins were revealed from the remaining eluates by immunoblotting with the indicated antibodies (upper frame).
The input corresponds to 30 mg of HEK293 proteins. Indicated under the panels are the percentages of binding proteins compared to
immunoprecipitation with the wild-type DDX6, after normalization using the amount of each immunoprecipitated FLAG protein.
Similar results were obtained in three to six independent immunoprecipitation experiments.
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Figure 5. DDX6 Targets and mRNA-Encoding Proteins Involved in Translation Initiation Are Enriched Among Genes Upregulated in
Individual S2
(A) A biotype distribution (according to Ensembl) of the differentially-expressed (DE) genes identified in S2.
(B) Pathway enrichment analysis revealed a significant enrichment of the GO terms ‘‘Biological Process’’ and ‘‘Molecular Function’’
related to protein translation, ribosome and RNA processing; it also revealed enrichment for the KEGG pathway ‘‘ribosome’’ among
the upregulated genes.
(legend continued on next page)
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initiation factor subunit mRNAs and 28 of the 85 expressed
ribosomal protein mRNAs were significantly upregulated
in S2, whereas none were significantly depleted
(Table S3). A subset of the DE genes (CNOT3, HNRNPH2,
DDX59, RPL10, etc.) encode RNA binding proteins also
known to be involved in ID (Table S4).
To investigate relationships between S20s transcriptomic
profile and DDX6 function, we took advantage of two data-
sets available from the ENCODE project, both from the
human erythroid cell line K562: (1) a DDX6 cross-linking
followed by immunoprecipitation (CLIP) experiment iden-
tifying mRNAs that bind to DDX6 and (2) a transcriptome
after induction of a stably-transfected DDX6 shRNA for
48 h identifying mRNAs differentially expressed after
DDX6 silencing. If the DDX6-Cys390Arg variant leads to a
defect in its function in mRNA decay, we would expect an
accumulation of these DDX6mRNA targets. Indeed, we first
observed that significantly enriched mRNAs in S2 fibro-
blasts were also enriched in ENCODE’s DDX6 CLIP experi-
mental data (Figure 5C, left panel), indicating their direct
binding to DDX6. Second, enriched mRNAs in S2 also
tended to be enriched in the DDX6-silencing dataset
(Figure 5C, right panel). Thus, in spite of the differences be-
tween the two cell types under comparison (dermal fibro-
blasts producing a p.Cys390Argþ/ variant DDX6 versus
an immortalized erythroid cell line transiently depleted
for DDX6), there was a common signature of enriched
mRNAs between the two. Furthermore, the enrichment
was even stronger for the mRNA subset that was enriched
in both the CLIP experiments and the DDX6 silencing
experiment (Figure 5C, right panel), indicating that the
mRNAs enriched in S2’s cells were probably decayed by a
DDX6-dependent mechanism that involved direct DDX6
binding.
We have recently shown that mRNAs regulated by
DDX6 at the level of decay are localized out of PBs.12
Accordingly, comparing S20s transcriptome to the mRNA
content of purified PBs showed that mRNAs that are en-
riched in S20s fibroblasts are excluded from PBs
(Figure 5D). In the same study, we showed that the
mRNAs that are targeted to PBs, in contrast, are regulated
at the level of translation. Although translation regulation
is not accessible in our transcriptome analysis, the fact
that PBs are drastically reduced in S2 strongly suggests
that DDX6-dependent translation repression is also
affected in these cells. Finally, the mRNAs accumulating
in S2 have a high GC content compared to other human
genes, whereas the mRNAs depleted are rather AU-rich
(Figure 5E). This is consistent with our recent study
showing that DDX6 is preferentially involved in the decay
of GC-rich mRNAs. Such a high GC content increases the
frequency of optimal codons and is therefore observed in
actively translated mRNAs.
Discussion
In this study, we describe five rare de novo missense vari-
ants, identified in individuals with ID, in the RNA heli-
case DDX6. Clinical, genetic, and functional data
demonstrated that these missense variants, inducing def-
icits in DDX6 functions, cause an autosomal-dominant
form of intellectual disability associated with mild dys-
morphic features. These deficits affect the ability of
DDX6 to assemble PBs—constitutive cytoplasmic RNP
granules that act in mRNA storage—resulting in their
drastic reduction in primary cells of affected individuals,
as well as when modeled in human cell lines. Further-
more, co-immunoprecipitation assays showed the patho-
genic variants affect DDX6 interactions with protein
partners, such as LSM14A and 4E-T, involved in PB as-
sembly, suggesting a mechanism for PB dysfunction
and subsequent deregulation of mRNA storage. Interac-
tions with other DDX6 protein partners (PAT1B, EDC3,
and EDC4) were differently impacted, depending on
the variants. The surface of DDX6 that interacts with
these different proteins was reported to be distinct,
though overlapping. Therefore, we did not expect that
different variants of DDX6 would alter all interactions
to the same extent. Additional defects included DDX6
dysfunction in the control of mRNA stability, as tran-
scriptomic analysis of S2 revealed an enrichment of
mRNAs that are regulated by DDX6 at the level of
decay,45 in particular mRNA encoding subunits of the
translation initiation factor eIF3 and ribosomal proteins
(Figure 5F). Many mRNAs also contain in their 50 UTR
a TOP motif that is responsible for their control
by the mTORC1 kinase (25 out of the 94 TOP
mRNAs previously reported46 were enriched in S2 cells).
Their deregulation could have consequences on the
control of cell proliferation/function inside and outside
of the CNS.46,47 Taken together, these findings
highlight crucial roles for DDX6 and/or PBs in proper
neurodevelopment.
The missense changes identified in affected individuals
cluster in two pairs of amino acids in conserved motifs of
(C) The mRNAs up- (orange boxes) and downregulated (green boxes) in subject 2 (S2) were analyzed for their enrichment in a DDX6
CLIP experiment (left panel) and their differential expression after DDX6 silencing (right panel), both in K562 cells. The analysis was
performed with various p value thresholds for the differential expression in S2, as indicated. The distribution of the whole dataset
(all) is given for comparison (gray boxes). The whiskers indicate the 10–90 percentiles. Upregulated mRNAs in S2 are preferential
DDX6 targets and preferentially upregulated after DDX6 depletion in an erythroid cell line.
(D) Upregulated mRNAs in S2 tend to be excluded from PBs. The mRNAs up- and downregulated in S2 were analyzed for their
enrichment in purified PBs, as in (C).
(E) Upregulated mRNAs in S2 tend to have a high GC content. In panels C–E, two-tail Mann-Whitney tests were performed with respect
to all mRNAs: ***p < 0.0005 and **p < 0.005.
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the DDX6 C-terminal RecA domain: residues 372–373,
which comprise the second half of the QxxR motif, and
390–391, which lie in motif V48 (Figures 2A and S1). The
substitutions p.Arg373Gln (S1) and p.His372Arg (S5) cause
significant alterations to residue properties and likely local
protein structure and function. Electrically-charged surface
residues like Arg373 are known to promote proper protein
folding through solvent interactions, and reactive histi-
dines are most common in protein active sites. The QxxR
motif is also involved in interdomain interactions with
motif Ia in vitro in the yeast DEAD-box protein
Mss116p,49 which was proposed to help form a continuous
RNA binding surface and stabilize bound RNA. The change
of Cys390 (S2) to a large, electrically-charged arginine, and
the conversions of Thr391 (S3 and S4) from a polar threo-
nine to non-polar, unreactive residues (proline and isoleu-
cine), also suggest destabilizing regional changes to the
RecA-2 domain. Our co-immunoprecipitation and comple-
mentation assays support these predictions with results
showing a dysfunction of the variant DDX6 proteins to
bind partners through this region and to assemble PBs,
respectively. Because the proband fibroblasts have a strong
PB deficiency despite the presence of one wild-type allele,
it raises the possibility that the DDX6 variants could
have some dominant-negative effect on PB assembly. We
have previously characterized a clearly dominant-negative
DDX6 variant (motif VI mutant HRIG) in an experiment
similar to the one described here (Figure S4B), and we
found that its expression completely suppressed PBs in
the presence of the endogenous DDX6 protein,11 which
is not the case for the probands’ variants. We would there-
fore favor the hypothesis that the low PB assembly results
from haploinsufficiency of the wild-type allele.
DDX6 is not the first gene encoding an RNA helicase
involved in monogenic forms of ID or NDD. The involve-
ment of DHX30 in ID was uncovered in 2017 when several
de novomissense variants also in the RecA domains were re-
ported in twelve individuals with ID, speech impairment,
and gait abnormalities.50 Pathogenic variants including
de novo truncating and missense changes in RecA domains
have also been recently reported in the DDX3X gene,51
located on the X chromosome, in females with ID, hypoto-
nia, movement disorders, and epilepsy.DDX3X now repre-
sents one of the genes most frequently mutated in ID; it is
involved in 0.5% of ID cases and 2% of female cases.52
Interestingly, after sequence alignment of DDX6 and
DDX3X, the Arg373 position found mutated in our cohort
corresponds to the Arg480 position recurrently mutated in
the DDX3X cohort of affected individuals, reinforcing the
functional importance of this amino acid and the QxxR
motif in DEAD-box proteins. LoF variants in another mem-
ber of this helicase family,DDX59, have also been reported
to cause an autosomal-recessive form of ID with features of
oral-facial-digital syndrome.53–55
Interestingly, the phenotypic traits observed in ourDDX6
cohort align well with the syndromes described in individ-
uals with pathogenic variants in DDX3X and DHX30.50–52
These include ID, DD, gait abnormalities, cardiac anomalies,
andcorpus callosumhypoplasia, aswell asdysmorphic facial
features (high forehead, a bulbous nasal tip, hypertelorism,
and arched eyebrows). Conversely, none of the individuals
withDDX6 variants have reported seizures, a feature present
in the DDX3X and DHX30 syndromes. This could be an
interesting delineation of theDDX6 cohort and give specific
biological insights into the specificity of each DExD/H-box
protein. However, seizures are present in only a subset of
the DDX3X and DHX30 cohorts (16% and 25%, respec-
tively), thus study of more individuals with the DDX6 syn-
drome is needed to completely exclude seizures as an absent
feature. Our cohort also exhibits a degree of variability in
their clinical presentations. Individuals S1 and S5 present
with mild abnormalities on brain MRI (corpus callosum
hypoplasia) and appear to be slightly more affected than
the others. Their amino acid changes (p.His372Arg and
p.Arg373Gln) lie in theQxxRmotif, suggesting that variants
in thismotif elicit a slightlymore severephenotype thanvar-
iants in the motif V region. In support of this, co-immuno-
precipitation studies demonstrated more drastic defects of
protein binding caused by the p.Arg373Gln variant. Because
differences in the proband’s genetic backgrounds are also
likely to contribute to phenotypic variability, the study of
more individuals with pathogenic DDX6 variation will be
required to fully answer this question.
DDX6 is widely expressed throughout tissues, and it has
some of the highest expression levels in the cerebellar hemi-
spheres. Its expression is regulated in a time-dependent
manner in the mouse neocortex during development,56
and it has been found to be expressed in both mouse57 and
human neural stem cells (NSCs) (data extracted from previ-
ous works58). DDX6 is further involved in the CNS; it in-
creases the activity of Let-7a, a microRNA important in
neuronal differentiation. DDX6 overexpression in mouse
NSCs leads to an increase in neuronal differentiation,
whereas loss of DDX6 function inhibits the formation of
new neurons.57 DDX3X was also found to be essential for
neuronal differentiation and migration, and its inactivation
in mice disturbs cortex development and leads to abnormal
distribution of neurons in the cortical plate.59 It is possible
the brain anomalies present in DDX6 individuals S1 and S5
result from impaired processes in NSC specification.
Although some evidence supports this idea, the exceedingly
heterogeneous nature of corpus callosumanomalies requires
further in vivoworktovalidatehowthesepathogenicvariants
would alter the proliferation, differentiation, ormigration of
neuronal precursors and synaptic functioning, as well as to
identify which mRNAs are deregulated in this cell type.
Wehave shown that ourDDX6variants result in failure to
form PBs efficiently, and they lead to a decreased number of
theseRNPgranules in thefibroblasts of affected individuals.
Lessel et al. recently showed thatDHX30missense variants,
in addition to altering the ability of DHX30 to bind RNA or
to exert its ATPase activity, increase the formation of
another significant type of RNP granules, stress granules,
and this process is associated with a decrease of global
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protein translation.50 The missense variants identified in
DDX3X were also shown to affect ATPase helicase activity
and lead to protein accumulation into RNP granules not
well characterized but harboring some translational activ-
ity.59RNPgranuledysfunction inneurons specifically could
relate to their polar, asymmetric nature. Indeed, there are a
variety of neuronal RNP granules, mostly described in den-
drites. Several types of dendritic granules contain PB com-
ponents and were initially called P-body-like structures60
or P-bodies.61 They are important in regulating local trans-
lation at the synapse, a process that is essential for synaptic
plasticity.62 However, further attempts to define these gran-
ules with the expression of DDX6 and decapping enzymes
suggested that these structures were more diverse in
neuronal processes than in other cells.63 In the neuronal
soma, RNP granulesmay be closer to fibroblast PBs in terms
of composition and function, but they have not been well
characterized. Repression by miRNAs also plays a major
role in the control of signaling pathways regulating several
steps of cortical development,64 therefore we can speculate
that thedifferent cytoplasmic foci that play roles in the stor-
age of miRNA targets are important for a proper develop-
ment of the brain.
The present study has taken effort to demonstrate that
rare changes in DDX6 cause PB and mRNA metabolism
dysfunction. These DDX6 dysfunctions were observed not
only by overexpressing DDX6 in immortalized cell lines
but also directly in affected individual’s primary fibroblasts
(individuals S1 and S2). The use of these non-neuronal cells
might only distantly reflect the actual disease pathogenesis
in affected individual’s brains and other organs. Further
transcriptomic and proteomic studies in neuronal cells
derived from primary fibroblasts or in vivo animal models
will shine more light on the specific mechanisms of
DDX6-associated pathogenesis in neurodevelopment.
In conclusion, our findings implicate rare de novomissense
variants in the second RecA domain of DDX6 in ID. These
variants significantly affect DDX6’s ability to assemble PBs,
resulting in their drastic reduction in cells, and, in the
affected individual whose transcriptomic data we have, the
significant alteration of the transcriptome landscape. We
suggest that rarevariants inDDX6beconsidered forpathoge-
nicity in pediatric cases of ID and that this RNA helicase be
added to the growing list of NDD- and ID-associated genes.
Lastly, together with the recent involvement of DDX3X
andDHX30 in ID and similar NDDs, these results also high-
light an emerging class of NDD involving RNA helicases.
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